Plaintiffs alleged that Bristol Myers-Squibb Company, a producer of the drug BuSpar ®, unlawfully maintained a monopoly in violation of federal and state antitrust and unfair competition laws. A $90 million settlement was preliminarily approved in April 2003. Cohen Milstein served as one of four co-lead counsel.